Effects of inflammatory cytokine gene polymorphisms on warfarin maintenance doses in Korean patients with mechanical cardiac valves
- 303 Downloads
Cytokines that are involved in inflammation are related to blood coagulation, which could indirectly affect warfarin dose requirements. This study aimed to examine the effects of inflammatory cytokine gene polymorphisms on warfarin dose requirements for Korean patients with mechanical heart valves. In total, 191 patients with mechanical heart valves who were on warfarin anticoagulation therapy and maintained INR levels of 2–3 for three consecutive occasions were retrospectively followed up. In addition to vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 (CYP) 2C9 polymorphisms, the interferon-γ, interleukin-1β (IL1B), interleukin-6, interleukin-10, transforming growth factor-β1 (TGFB1), tumor necrosis factor-α, and C-reactive protein genotypes were determined. The predictive contribution of age, VKORC1, and CYP2C9 to variability was 46.0 %. The addition of IL1B and TGFB1 polymorphisms increased the R 2 to 48.8 % for stable dose requirements, and significantly higher doses were found, especially when the TGFB1 CC genotype was combined with the IL1B TT genotype. Based on the results, it was concluded that inflammatory cytokine genes, such as TGFB1 and IL1B, can be predictive variables for stable warfarin doses in Korean patients.
KeywordsWarfarin Stable dose INR Genotype Cytokine genes
Conflict of interest
We declare no conflict of interest.
- Almeida, O.P., P.E. Norman, R. Allcock, F. van Bockxmeer, G.J. Hankey, K. Jamrozik, and L. Flicker. 2009. Polymorphisms of the CRP gene inhibit inflammatory response and increase susceptibility to depression: The Health in Men Study. International Journal of Epidemiology 38: 1049–1059.PubMedCentralPubMedCrossRefGoogle Scholar
- Bennermo, M., C. Held, F. Green, L.E. Strandberg, C.G. Ericsson, L.O. Hansson, H. Watkins, A. Hamsten, and P. Tornvall. 2004. Prognostic value of plasma interleukin-6 concentrations and the 174 G>C and 572 G>C promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis. Atherosclerosis 174: 157–163.PubMedCrossRefGoogle Scholar
- Caldwell, M.D., T. Awad, J.A. Johnson, B.F. Gage, M. Falkowski, P. Gardina, J. Hubbard, Y. Turpaz, T.Y. Langaee, C. Eby, C.R. King, A. Brower, J.R. Schmelzer, I. Glurich, H.J. Vidaillet, S.H. Yale, K. Qi Zhang, R.L. Berg, and J.K. Burmester. 2008. CYP4F2 genetic variant alters required warfarin dose. Blood 111: 4106–4112.PubMedCentralPubMedCrossRefGoogle Scholar
- De Jonge, E., P.E. Dekkers, A.A. Creasey, C.E. Hack, S.K. Paulson, A. Karim, J. Kesecioglu, M. Levi, S.J. van Deventer, and T. van Der Poll. 2000. Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 95: 1124–1129.PubMedGoogle Scholar
- Hutchinson, J.V., V. Pravica, and P.J. Sinnot. 1998. Genetic regulation of cytokine synthesis: Consequences for acute and chronic organ allograft rejection. Graft 1: 15–21.Google Scholar
- Lazo-Langner, A., G.A. Knoll, P.S. Wells, N. Carson, and M.A. Rodger. 2006. The risk of dialysis access thrombosis is related to the transforming growth factor-beta1 production haplotype and is modified by polymorphisms in the plasminogen activator inhibitor-type 1 gene. Blood 108: 4052–4058.PubMedCrossRefGoogle Scholar
- Lindahl, B., H. Toss, A. Siegbahn, P. Venge, and L. Wallentin. 2001. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. The New England Journal of Medicine 343: 1139–1147.CrossRefGoogle Scholar
- Pravica, V., C. Perrey, A. Stevenes, J.H. Lee, and I.V. Hutchinson. 2000. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: Absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Human Immunology 61: 863–866.PubMedCrossRefGoogle Scholar
- Wilson, A.G., J.A. Symon, T. McDowell, H.O. McDevitt, and G.W. Duff. 1997. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proceedings of the National Academy of Sciences of the United States of America 94: 3195–3199.PubMedCentralPubMedCrossRefGoogle Scholar